Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib

Donavan T. Cheng, Talia N. Mitchell, Ahmet Zehir, Ronak H. Shah, Ryma Benayed, Aijazuddin Syed, Raghu Chandramohan, Zhen Yu Liu, Helen H. Won, Sasinya N. Scott, A. Rose Brannon, Catherine O'Reilly, Justyna Sadowska, Jacklyn Casanova, Angela Yannes, Jaclyn F. Hechtman, Jinjuan Yao, Wei Song, Dara S. Ross, Alifya Oultache, Snjezana Dogan, Laetitia Borsu, Meera Hameed, Khedoudja Nafa, Maria E. Arcila, Marc Ladanyi, Michael F. Berger, Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology The Journal of Molecular Diagnostics. ,vol. 17, pp. 251- 264 ,(2015) , 10.1016/J.JMOLDX.2014.12.006

Kenneth S Thress, Cloud P Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J Carl Barrett, Pasi A Jänne, Geoffrey R Oxnard, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M Nature Medicine. ,vol. 21, pp. 560- 562 ,(2015) , 10.1038/NM.3854

Helena A. Yu, Shaozhou K. Tian, Alexander E. Drilon, Laetitia Borsu, Gregory J. Riely, Maria E. Arcila, Marc Ladanyi, Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain JAMA Oncology. ,vol. 1, pp. 982- 984 ,(2015) , 10.1001/JAMAONCOL.2015.1066

Zofia Piotrowska, Matthew J. Niederst, Chris A. Karlovich, Heather A. Wakelee, Joel W. Neal, Mari Mino-Kenudson, Linnea Fulton, Aaron N. Hata, Elizabeth L. Lockerman, Anuj Kalsy, Subba Digumarthy, Alona Muzikansky, Mitch Raponi, Angel R. Garcia, Hillary E. Mulvey, Melissa K. Parks, Richard H. DiCecca, Dora Dias-Santagata, A. John Iafrate, Alice T. Shaw, Andrew R. Allen, Jeffrey A. Engelman, Lecia V. Sequist, Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor Cancer Discovery. ,vol. 5, pp. 713- 722 ,(2015) , 10.1158/2159-8290.CD-15-0399

Shirish M. Gadgeel, Fadlo R. Khuri, Jeff A. Engelman, Marianna Koczywas, Arun Rajan, Alicyn K. Campbell, Diana Gernhardt, Ana Ruiz-Garcia, Stephen Letrent, Jane Liang, Ian Taylor, Joseph P. O'Connell, Pasi A. Jänne, Karen L. Reckamp, Giuseppe Giaccone, D. Ross Camidge, A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. ,vol. 120, pp. 1145- 1154 ,(2014) , 10.1002/CNCR.28561

Dalia Ercan, Hwan Geun Choi, Cai-Hong Yun, Marzia Capelletti, Ting Xie, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne, EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clinical Cancer Research. ,vol. 21, pp. 3913- 3923 ,(2015) , 10.1158/1078-0432.CCR-14-2789

James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, Chun-Ming Tsai, Tony Shu Kam Mok, Martin Schuler, Nobuyuki Yamamoto, Chong-Jen Yu, Sai-Hong I Ou, Caicun Zhou, Daniel Massey, Victoria Zazulina, Yi-Long Wu, Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 The Lancet Oncology. ,vol. 16, pp. 830- 838 ,(2015) , 10.1016/S1470-2045(15)00026-1

, Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network Nature. ,vol. 511, pp. 543- 550 ,(2014) , 10.1038/NATURE13385

Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy, Mohammad S. Esfahani, Aaron M. Newman, Henry J. Haringsma, David M. Kurtz, Henning Stehr, Florian Scherer, Chris A. Karlovich, Thomas C. Harding, Kathleen A. Durkin, Gregory A. Otterson, W. Thomas Purcell, D. Ross Camidge, Jonathan W. Goldman, Lecia V. Sequist, Zofia Piotrowska, Heather A. Wakelee, Joel W. Neal, Ash A. Alizadeh, Maximilian Diehn, Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients Nature Communications. ,vol. 7, pp. 11815- 11815 ,(2016) , 10.1038/NCOMMS11815

Matteo Canale, Elisabetta Petracci, Angelo Delmonte, Elisa Chiadini, Claudio Dazzi, Maximilian Papi, Laura Capelli, Claudia Casanova, Nicoletta De Luigi, Marita Mariotti, Alessandro Gamboni, Rita Chiari, Chiara Bennati, Daniele Calistri, Vienna Ludovini, Lucio Crinò, Dino Amadori, Paola Ulivi, Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors Clinical Cancer Research. ,vol. 23, pp. 2195- 2202 ,(2017) , 10.1158/1078-0432.CCR-16-0966